Latest stories

No image

IRE strengthens its leadership in radiopharmaceutical production with the arrival of the 30 MeV IBA cyclotron at its site

No image

IRE ELiT and Grand Pharmaceutical (China) Co., Ltd. announce partnership for Galli Eo (Gallium-68 generator) distribution in China

No image

IRE ELiT and PI Medical Diagnostic Equipment announce commercial partnership for Galli Ad generator in the Netherlands and Flanders

No image

IRE moves to 100% LEU (Low Enriched Uranium) conversion

No image

The fight against cancer intensified thanks to SCK CEN and the IRE

SMART takes critical step towards the production of medical isotope Mo-99 without uranium

SMART takes critical step towards the production of medical isotope Mo-99 without uranium

No image

Cardinal Health™ Nuclear & Precision Health Solutions and IRE ELiT support the growing demand for Ga-68 labeled radiopharmaceuticals

No image

IRE ELiT and ROTOP Pharmaka enter into a distribution partnership in Germany for 68Germanium / 68Gallium generator

No image

IBA selected to equip IRE’s new radioisotope production unit dedicated to cancer diagnosis

No image

IRE supplies a first commercial batch of LEU-based Mo-99

No image

IRE and SCK CEN Partnership on lutetium-177 production: a ray of hope for prostate cancer treatment

Contact us

Bérénice Pignol
IRE - IRE ELiT

Get updates in your mailbox

By clicking "Subscribe" I confirm I have read and agree to the Privacy Policy.

About IRE and IRE ELiT

Founded in 1971 and based in Fleurus, in the province of Hainaut, the National Institute of Radioelements (IRE), a Belgian foundation of public interest, is one of the very few players worldwide capable of producing and developing certain radioisotopes used in nuclear medicine.

IRE is notably the global leader in the production of Molybdenum‑99, the “parent” isotope of metastable Technetium-99m. Using a gamma camera, this isotope makes it possible to observe a patient’s internal anatomy in real time (heart, bones, lungs, thyroid, brain, kidneys, etc.) and to diagnose certain diseases at an early stage. IRE supplies around 50% of European demand for Mo-99 and 25% of global production, a share that can rise to up to 65% during periods of global supply tension.

At the same time, IRE ELiT, a subsidiary founded in 2010, is one of the two global leaders in pharmaceutical‑grade Ge-68/Ga-68 generators for human use. Gallium-68 (Ga-68) is a key isotope for high‑precision PET imaging - particularly for neuroendocrine tumours and prostate cancer - and for personalised medicine in radioligand therapy (RLT) strategies. IRE-ELiT’s Ga-68 generators are currently marketed in around 40 countries.

Beyond its production activities aimed at improving patient care and quality of life, IRE also contributes - through its IRE Lab division - to environmental protection and monitoring. The Institute offers services for radioactivity measurement in various samples, radiological characterisation of waste and contaminated materials, as well as consultancy and technical support in the radiological and nuclear fields.

Today, IRE and IRE ELiT employ 300 people, all committed to translating cutting‑edge scientific advances into diagnostic and therapeutic solutions for patients.

More information: www.ire.eu

Contact

www.ire.eu